The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

Current dosing algorithms do not account for genetic and environmental factors for warfarin dose determinations. This study investigated the contribution of age, CYP2C9 and VKORC1 genotype, and body size to warfarin-dose requirements. Studied were 297 patients with stable anticoagulation with a target international normalized ratio (INR) of 2.0 to 3.0. Genetic analyses for CYP2C9 (*2 and *3 alleles) and VKORC1 (-1639 polymorphism) were performed and venous INR and plasma R- and S-warfarin concentrations determined. The mean warfarin daily dose requirement was highest in CYP2C9 homozygous wild-type patients, compared with those with the variant *2 and *3 alleles (P < .001) and highest in patients with the VKORC1 (position -1639) GG genotype compared with those with the GA genotype and the AA genotype (P < .001). Mean warfarin daily dose requirements fell by 0.5 to 0.7 mg per decade between the ages of 20 to 90 years. Age, height, and CYP2C9 genotype significantly contributed to S-warfarin and total warfarin clearance, whereas only age and body size significantly contributed to R-warfarin clearance. The multivariate regression model including the variables of age, CYP2C9 and VKORC1 genotype, and height produced the best model for estimating warfarin dose (R2 = 55%). Based upon the data, a new warfarin dosing regimen has been developed. The validity of the dosing regimen was confirmed in a second cohort of patients on warfarin therapy.

[1]  David C. Anderson,et al.  Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1996, Archives of internal medicine.

[2]  Donald Martin,et al.  Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study , 1993, Annals of Internal Medicine.

[3]  F. Kamali,et al.  The influence of age, liver size and enantiomer concentrations on warfarin requirements. , 1995, British journal of clinical pharmacology.

[4]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[5]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[6]  A. Hofman,et al.  Patients with an ApoE ϵ4 allele require lower doses of coumarin anticoagulants , 2005, Pharmacogenetics and genomics.

[7]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[8]  A. Breckenridge,et al.  The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. , 1988, British journal of clinical pharmacology.

[9]  A. Hofman,et al.  Patients with an ApoE e4 allele require lower doses of coumarin anticoagulants , 2005 .

[10]  Anticoagulants in the Secondary Prevention of Events in Coronary Group.  Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction , 1994, The Lancet.

[11]  D. P. Bentley,et al.  Flexible induction dose regimen for warfarin and prediction of maintenance dose. , 1984, British medical journal.

[12]  E. Spina,et al.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance , 2002, Clinical pharmacology and therapeutics.

[13]  D. Tregouet,et al.  Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. , 2005, Blood.

[14]  R. Beyth,et al.  A Multicomponent Intervention To Prevent Major Bleeding Complications in Older Patients Receiving Warfarin , 2000, Annals of Internal Medicine.

[15]  F. Kamali,et al.  Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin , 2004, Clinical pharmacology and therapeutics.

[16]  K. Hampton,et al.  A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. , 2000, Age and ageing.

[17]  O. Wallerman,et al.  Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors , 2004, The Pharmacogenomics Journal.

[18]  I. Ieiri,et al.  Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. , 2003, Blood.

[19]  F. Kamali,et al.  The Influence of (R)- and (S)-Warfarin, Vitamin K and Vitamin K Epoxide upon Warfarin Anticoagulation , 2000, Thrombosis and Haemostasis.

[20]  J. Hirsh,et al.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. , 2001, Chest.

[21]  J. Vandenbroucke,et al.  Optimal oral anticoagulant therapy in patients with mechanical heart valves. , 1995, The New England journal of medicine.

[22]  W. J. Hamilton,et al.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.

[23]  F. Kamali,et al.  Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. , 2004, Pharmacogenetics.

[24]  M. Moia,et al.  CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy , 2004, Clinical pharmacology and therapeutics.

[25]  T J Wilkinson,et al.  Evaluation of a warfarin initiation protocol for older people , 2003, Internal medicine journal.

[26]  D. Tashkin.  Multiple dose regimens. Impact on compliance. , 1995, Chest.

[27]  Howard L McLeod,et al.  Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin , 2003, Thrombosis and Haemostasis.

[28]  T. Baglin,et al.  Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. , 2000, Blood.

[29]  J. Hirsh,et al.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. , 1998, Chest.

[30]  Anticoagulants in the Secondary Prevention of Events in Coronary Group.  Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction , 1994, The Lancet.

[31]  J. Jespersen,et al.  Multicentre randomised study of computerised anticoagulant dosage , 1998, The Lancet.